Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells
5 affiliations
- 1Department of Molecular Biology and Human Genetics, Tzu-Chi University, Hualien 970, Taiwan
- 2Department of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei 110, Taiwan
- 3Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan
- 4Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
- 5Department of Chemistry, Tamkang University, Tamsui Dist., New Taipei City 251, Taiwan
Abstract
Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.
Related
- Phytochemical analyses, antimicrobial, antioxidant and anticancer activities of endophytic fungi from leaves of Reseda pruinosa
- Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses
- Evaluation of Unique Multidentate Fluoroquinolones as Potential Anticancer and Antimicrobial Compounds Reinforced by Docking Mechanistic Studies on Topoisomerase II and Glyoxalase I with Dual Antioxidative–Anti-Inflammatory Effects
- Integrated In vitro and in vivo evaluation of anticancer potentials of two clerodane diterpenes isolated from Psidium guajava (L.) through molecular docking approaches
- Evaluation of the Anticancer Potential of Compound 107 via the VEGFA and VEGFR2 (KDR) Signaling Pathway in Colorectal Cancer: Integrative Analysis of Clinical, In Silico, and In Vitro Approaches
BibTeX
@article{lin2026anticancer,
title = {{Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells}},
author = {Guan-Ling Lin and Jen-Che Chang and Yue-Cen Lai and Te-Sheng Lien and Der-Shan Sun and Ching-Feng Cheng and Lian-Fu Yang and Ruo-Chia Tseng and Yu-Jui Su and Hsin-Ying Wu and Tzenge-Lien Shih and Hsin-Hou Chang},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210279},
url = {https://www.mdpi.com/1422-0067/27/22/10279},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells
AU - Guan-Ling Lin
AU - Jen-Che Chang
AU - Yue-Cen Lai
AU - Te-Sheng Lien
AU - Der-Shan Sun
AU - Ching-Feng Cheng
AU - Lian-Fu Yang
AU - Ruo-Chia Tseng
AU - Yu-Jui Su
AU - Hsin-Ying Wu
AU - Tzenge-Lien Shih
AU - Hsin-Hou Chang
PY - 2026
DA - 2026/11/16
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210279
UR - https://www.mdpi.com/1422-0067/27/22/10279
AB - Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.
SN - 1422-0067
ER -